JPM vs MKTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MKTX exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and a very strong balance sheet characterized by low leverage (Debt/Equity 0.25). While the current price of $174.56 sits below the growth-based intrinsic value of $196.18, it remains significantly elevated compared to the defensive Graham Number of $69.22. The company shows impressive earnings growth (45.3% YoY), yet this is decoupled from stagnant revenue growth (3.5%), suggesting efficiency gains rather than market expansion. A severely bearish technical trend (0/100) and poor long-term price performance (-65.4% over 5 years) offset the positive analyst consensus.
Compare Another Pair
Related Comparisons
JPM vs MKTX: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and MarketAxess Holdings Inc. (MKTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.